CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML

Autor: Silva, Harrison J. ¹, Martin, Grace ¹, Birocchi, Filippo ¹, Wehrli, Marc ¹, Kann, Michael C. ¹, Supper, Valentina ¹, Parker, Aiyana ¹, Graham, Charlotte ¹, Bratt, Alexandra ¹, Bouffard, Amanda ¹, Donner, Hannah ¹, Escobar, Giulia ¹, Takei, Hana ¹, Armstrong, Alexander ¹, Goncalves, Sadie ¹, Berger, Trisha R. ¹, Choi, Bryan D. ^{2, 3, 4}, Maus, Marcela V. ^{1, 2, 3}, Leick, Mark B. ^{1, 2, 3, ∗}

Publikováno v: In Blood October 2024

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7.

Autor: Kann MC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA., Schneider EM; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA., Almazan AJ; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA., Lane IC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA., Bouffard AA; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA., Supper VM; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA., Takei HN; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA., Tepper A; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA., Leick MB; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Blood and Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA., Larson RC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Ebert BL; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Howard Hughes Medical Institute, Bethesda, MD, USA., Maus MV; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA. mvmaus@mgh.harvard.edu.; Harvard Medical School, Boston, MA, USA. mvmaus@mgh.harvard.edu.; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA. mvmaus@mgh.harvard.edu., Jan M; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.

Publikováno v: Leukemia [Leukemia] 2024 Mar; Vol. 38 (3), pp. 590-600. Date of Electronic Publication: 2023 Dec 20.